Complex haplotypic effects of the ABCB1 gene on epilepsy treatment response

被引:121
作者
Hung, CC
Tai, JJ
Lin, CJ
Lee, MJ
Liou, HH
机构
[1] Natl Taiwan Univ Hosp, Sch Pharm, Taipei 100, Taiwan
[2] Natl Taiwan Univ, Coll Med, Dept Pharmacol, Taipei 100, Taiwan
[3] Natl Taiwan Univ, Coll Med, Dept Pharmacol, Taipei 100, Taiwan
[4] Natl Taiwan Univ Hosp, Grad Inst Clin Pharm, Taipei 100, Taiwan
[5] Natl Taiwan Univ Hosp, Grad Inst Epidemiol, Taipei 100, Taiwan
[6] Natl Taiwan Univ Hosp, Dept Neurol, Taipei 100, Taiwan
[7] Natl Taiwan Univ Hosp, Dept Med Genet, Taipei 100, Taiwan
关键词
epilepsy; haplotype; linkage disequilibrium; MDR1; multi-drug resistance;
D O I
10.1517/14622416.6.4.411
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives: The aim of this study was to investigate the association of the complex haplotype system of the adenosine triphosphate-binding cassette 131 (ABCB1) gene with the epilepsy treatment response. Methods and results: Ten polymorphisms were genotyped in 108 drug-resistant epileptic patients, 223 seizure-free patients and 287 normal controls. Highly significant linkage disequilibrium was shown among exon 12 C1 236T, exon 21 G2677T and exon 26 C3435T. Haplotypic analysis demonstrated that patients with the CGC, TGC, and TTT haplotypes were more likely to be drug resistant. Further analysis of haplotype combinations demonstrated that drug-resistant patients tended to have the CGC/CGC, CGC/TGC, CGC/TTT, and TGC/TTT haplotype combinations over the seizure-free patients and controls (all p-values < 0.0001). In contrast, patients with the TTC/TTC, TTC/CGT, TTC/TGT, CGT/CGT and TGT/CGT haplotype combinations were more likely to be seizure-free (all p-values < 0.0001 except CGT/CGT [p = 0.0063]). Conclusion: Our results showed that the three loci, C1236T, G2677T and C3435T, jointly influenced the treatment response for epileptic patients. They should be regarded together as a complex polymorphic drug-response system. These findings suggest that examination of the haplotypes of the three loci could be useful in predicting drug resistance in epilepsy.
引用
收藏
页码:411 / 417
页数:7
相关论文
共 31 条
[11]   Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene [J].
Johne, A ;
Köpke, K ;
Gerloff, T ;
Mai, I ;
Rietbrock, S ;
Meisel, C ;
Hoffmeyer, S ;
Kerb, R ;
Fromm, MF ;
Brinkmann, U ;
Eichelbaum, M ;
Brockmöller, J ;
Cascorbi, I ;
Roots, I .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (05) :584-594
[12]   Identification of functionally variant MDR1 alleles among European Americans and African Americans [J].
Kim, RB ;
Leake, BF ;
Choo, EF ;
Dresser, GK ;
Kubba, SV ;
Schwarz, UI ;
Taylor, A ;
Xie, HG ;
McKinsey, J ;
Zhou, S ;
Lan, LB ;
Schuetz, JD ;
Schuetz, EG ;
Wilkinson, GR .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 70 (02) :189-199
[13]   Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene [J].
Kroetz, DL ;
Pauli-Magnus, C ;
Hodges, LM ;
Huang, CC ;
Kawamoto, M ;
Johns, SJ ;
Stryke, D ;
Ferrin, TE ;
DeYoung, J ;
Taylor, T ;
Carlson, EJ ;
Herskowitz, I ;
Giacomini, KM ;
Clark, AG .
PHARMACOGENETICS, 2003, 13 (08) :481-494
[14]   Potential role of drug transporters in the pathogenesis of medically intractable epilepsy [J].
Kwan, P ;
Brodie, TJ .
EPILEPSIA, 2005, 46 (02) :224-235
[15]   Role of multidrug transporters in pharmacoresistance to antiepileptic drugs [J].
Löscher, W ;
Potschka, H .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 301 (01) :7-14
[16]  
MacDonald BK, 2000, ANN NEUROL, V48, P833, DOI 10.1002/1531-8249(200012)48:6<833::AID-ANA3>3.0.CO
[17]  
2-U
[18]   Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects [J].
Nakamura, T ;
Sakaeda, T ;
Horinouchi, M ;
Tamura, T ;
Aoyama, N ;
Shirakawa, T ;
Matsuo, M ;
Kasuga, M ;
Okumura, K .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (04) :297-303
[19]   Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan [J].
Sai, K ;
Kaniwa, N ;
Itoda, M ;
Saito, Y ;
Hasegawa, R ;
Komamura, K ;
Ueno, K ;
Kamakura, S ;
Kitakaze, M ;
Shirao, K ;
Minami, H ;
Ohtsu, A ;
Yoshida, T ;
Saijo, N ;
Kitamura, Y ;
Kamatani, N ;
Ozawa, S ;
Sawada, J .
PHARMACOGENETICS, 2003, 13 (12) :741-757
[20]   Pharmacogenetics of MDR1 and its impact on the pharmacokinetics of drugs and pharmacodynamics [J].
Sakaeda, T ;
Nakamura, T ;
Okumura, K .
PHARMACOGENOMICS, 2003, 4 (04) :397-410